Association of Urinary Liver-type Fatty Acid-binding Protein with Renal Functions and Antihyperglycemic Drug Use in Type 2 Diabetic Nephropathy Patients

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Feb 25

PMID 36840803

Authors

Kaname Hirowatari

Naoya Kawano

Affiliations

Soon will be listed here.

Abstract

Purpose: In diabetic nephropathy exacerbation, a reduction in the estimated glomerular filtration rate (eGFR) without raised albuminuria or proteinuria has been frequently observed. This study aimed to clarify the clinical usefulness of urinary liver-type fatty acid-binding protein (L-FABP) in the exacerbation of diabetic nephropathy in type 2 diabetes.

Methods: A cross-sectional study and a retrospective observational study of 227 patients with type 2 diabetes were conducted to investigate the relationship between urinary L-FABP and renal dysfunction. Changes in urinary L-FABP with or without additional administration of antihyperglycemic drugs were examined in 63 patients.

Results: Baseline urinary L-FABP was significantly associated with baseline eGFR (ρ = -0.34, p < 0.001) and baseline albuminuria (ρ = 0.64, p < 0.001). In multivariate regression analysis, baseline urinary L-FABP was a significant independent factor for eGFR reduction [β = -0.348, 95% confidence interval (CI) = -0.482 to -0.214, p < 0.001]. Cox regression analysis showed that patients with a baseline urinary L-FABP above 6.5 μg/g creatinine exhibited a higher hazard ratio (HR) for the renal dysfunction surrogate end point (HR = 15.00, 95% CI 3.640-61.40, p < 0.001). In logistic regression analysis, administration of sodium glucose cotransporter-2 inhibitors was associated with a statistically significant reduction in urinary L-FABP levels, independent of changes in systolic blood pressure, glycosylated hemoglobin, and eGFR (odds ratio = 0.75, 95% CI 0.56-0.99, p = 0.04).

Conclusion: Urinary L-FABP may be associated with the future decrease in renal functions in type 2 diabetic nephropathy patients. Additionally, urinary L-FABP could be used as a marker of the effectiveness of diabetic nephropathy treatment.

References

Fiseha T, Tamir Z . Urinary Markers of Tubular Injury in Early Diabetic Nephropathy. Int J Nephrol. 2016; 2016:4647685. PMC: 4884862. DOI: 10.1155/2016/4647685. View

Kosaki K, Kamijo-Ikemori A, Sugaya T, Tanahashi K, Kumagai H, Sawano Y . Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals. Clin Exp Nephrol. 2017; 21(5):810-817. DOI: 10.1007/s10157-017-1385-x. View

Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S . Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care. 2011; 34(3):691-6. PMC: 3041209. DOI: 10.2337/dc10-1392. View

Matsushita K, Chen J, Sang Y, Ballew S, Shimazaki R, Fukagawa M . Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016; 90(5):1109-1114. DOI: 10.1016/j.kint.2016.08.003. View

Coresh J, Turin T, Matsushita K, Sang Y, Ballew S, Appel L . Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014; 311(24):2518-2531. PMC: 4172342. DOI: 10.1001/jama.2014.6634. View

Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T . Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013; 424:104-8. DOI: 10.1016/j.cca.2013.05.020. View

Chou K, Lee C, Chen C, Sun C . Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS One. 2013; 8(1):e54863. PMC: 3551928. DOI: 10.1371/journal.pone.0054863. View

Thi T, Gia B, Thi H, Thi T, Thanh H . Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem. 2020; 39(2):224-230. PMC: 7526021. DOI: 10.2478/jomb-2019-0037. View

Araki S, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S . Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care. 2012; 36(5):1248-53. PMC: 3631864. DOI: 10.2337/dc12-1298. View

10.

Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T . Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol. 2016; 15:76. PMC: 4869394. DOI: 10.1186/s12933-016-0396-3. View

11.

Makino H, Matsuo M, Hishida A, Koezuka R, Tochiya M, Ohata Y . Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study. Diabetol Int. 2019; 10(2):148-152. PMC: 6506485. DOI: 10.1007/s13340-018-0376-9. View

12.

Kitada M, Tsuda S, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K . Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care. 2017; 5(1):e000391. PMC: 5530236. DOI: 10.1136/bmjdrc-2017-000391. View

13.

Garofalo C, Borrelli S, Liberti M, Andreucci M, Conte G, Minutolo R . SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Kaunas). 2019; 55(6). PMC: 6630922. DOI: 10.3390/medicina55060268. View

14.

Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y . Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig. 2019; 10(6):1510-1517. PMC: 6825940. DOI: 10.1111/jdi.13064. View

15.

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S . Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res. 2015; 47(9):686-92. DOI: 10.1055/s-0034-1395609. View

16.

Panchapakesan U, Pegg K, Gross S, Gangadharan Komala M, Mudaliar H, Forbes J . Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?. PLoS One. 2013; 8(2):e54442. PMC: 3563635. DOI: 10.1371/journal.pone.0054442. View

17.

Ni L, Yuan C, Chen G, Zhang C, Wu X . SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020; 19(1):98. PMC: 7320582. DOI: 10.1186/s12933-020-01071-y. View

18.

Tumminia A, Graziano M, Vinciguerra F, Lomonaco A, Frittita L . Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience. Prim Care Diabetes. 2020; 15(2):283-288. DOI: 10.1016/j.pcd.2020.10.002. View